Biography

Dr Kaplan received her medical degree from Dartmouth Medical School in Hanover, NH. She completed her pediatric residency training at Harvard Children's Hospital Boston and Boston Medical Center. Following residency Dr Kaplan pursued a fellowship in Pediatric Hematology and Oncology at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center, where she served as Chief Fellow. She did her postdoctoral research work in the laboratory of Dr. David Lyden. She was appointed Assistant Professor at Weill Cornell Medical College and Assistant Member at Memorial Sloan Kettering Cancer Center in 2006. In the fall of 2010 she joined the Pediatric Oncology Branch of the NCI. She is a clinician and physician scientist with active translational and clinical research interests focused on the mechanism of cancer spread. Dr Kaplan has been the recipient of several grants including the Charles, Lillian and Betty Neuwirth Clinical Scholar in Pediatric Oncology, Doris Duke Charitable Career Development Award, a co-investigator in the Komen Foundation Investigator-Initiated Award, Hope Street Kids grant award, ASCO young investigator award, and the Association for Research of Childhood Cancer. 

Research Intrest

Cancer Biology, Stem Cell Biology 

List of Publications
Acharya SS, Kaplan RN, Macdonald D, Fabiyi OT, DiMichele D, et al. (2011) Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 117: 2484-93.
Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, et al.(2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Med. 18: 883-91.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, et al. (2013) The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis. Neoplasia. 15: 848-62.
Zhang H, Maric I, Diprima MJ, Khan J, Orentas RJ, et al. (2013) Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 122: 1105-13.
Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, et al. (2014) Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 6: 237ra67,